Clinical Trial

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

Study acronym: DUET ENCORE-UC
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops ulcers).
Protocol Amendment History 3 changes
notable Trial sites expanded: 6 -> 26 locations 2026-07-07
critical Recruitment opened 2026-06-09
notable Trial sites expanded: 0 -> 6 locations 2026-06-09
Trial Details
NCT Number NCT07577856
Lead Sponsor Janssen Research & Development, LLC
Conditions Colitis, Ulcerative
Enrollment 644 participants
Start Date 2026-05-23
Primary Completion 2028-08-11 (estimated)
Study Completion 2030-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-06